[1]	ACOG. Hereditary cancer syndromes and risk assessment:ACOG COMMITTEE OPINION,Number 793[J]. Obstet Gynecol, 2019, 134(6):e143-e149. DOI:10.1097/AOG.0000000000003562. 本文引用 [1]

[2]	Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality[J]. JAMA, 2010, 304(9):967-975. DOI:10.1001/jama.2010.1237. 本文引用 [1]

[3]	中国抗癌协会肿瘤内分泌专业委员会, 中国优生科学协会女性生殖道疾病诊治分会,中国优生科学协会肿瘤生殖学分会.遗传性妇科肿瘤高风险人群管理专家共识(2020)[J]. 中国实用妇科与产科杂志, 2020, 36(9):825-834. DOI:10.19538/j.fk2020090109. 本文引用 [4]

[4]	World Health Organization. WHO handbook for guideline development,2nd Edition[EB/OL].( 2014-12-18). [2025-5-24]. https://www.who.int/publications/i/item/9789241548960. https://www.who.int/publications/i/item/9789241548960 本文引用 [1]

[5]	陈耀龙, 杨克虎, 王小钦, 等. 中国制订/修订临床诊疗指南的指导原则(2022版)[J]. 中华医学杂志, 2022, 102(10):697-703. DOI:10.3760/cma.j.cn112137-20211228-02911. 本文引用 [1]

[6]	Guyatt GH, Oxman AD, Vist GE, et al. GRADE:an emerging consensus on rating quality of evidence and strength of recommendations[J]. BMJ, 2008, 336(7650):924-926. DOI:10.1136/bmj.39489.470347.AD. 本文引用 [1]

[7]	Paluch-Shimon S, Cardoso F, Sessa C, et al. Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes:ESMO Clinical Practice Guidelines for cancer prevention and screening[J]. Ann Oncol, 2016, 27(suppl 5):v103-v110. DOI:10.1093/annonc/mdw327. 本文引用 [1]

[8]	ACOG. Practice Bulletin No 182:hereditary breast and ovarian cancer syndrome[J]. Obstet Gynecol, 2017, 130(3):e110-e126. DOI:10.1097/AOG.0000000000002296. 本文引用 [1]

[9]	Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history:a combined analysis of 22 studies[J]. Am J Hum Genet, 2003, 72(5):1117-1130. DOI:10.1086/375033. 本文引用 [1]

[10]	van Asperen CJ, Brohet RM, Meijers-Heijboer EJ, et al. Cancer risks in BRCA2 families:estimates for sites other than breast and ovary[J]. J Med Genet, 2005, 42(9):711-719. DOI:10.1136/jmg.2004.028829. 本文引用 [1]

[11]	Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance[J]. J Clin Oncol, 2007, 25(11):1329-1333. DOI:10.1200/JCO.2006.09.1066. 本文引用 [1]

[12]	Mavaddat N, Peock S, Frost D, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers:results from prospective analysis of EMBRACE[J]. J Natl Cancer Inst, 2013, 105(11):812-822. DOI:10.1093/jnci/djt095. 本文引用 [1]

[13]	Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast,ovarian,and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers[J]. JAMA, 2017, 317(23):2402-2416. DOI:10.1001/jama.2017.7112. 本文引用 [1]

[14]	Mersch J, Jackson MA, Park M, et al. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian[J]. Cancer, 2015, 121(2):269-275. DOI:10.1002/cncr.29041. 本文引用 [1]

[15]	Fanale D, Pivetti A, Cancelliere D, et al. BRCA1/2 variants of unknown significance in hereditary breast and ovarian cancer(HBOC) syndrome:Looking for the hidden meaning[J]. Crit Rev Oncol Hematol, 2022,172:103626. DOI:10.1016/j.critrevonc.2022.103626. 本文引用 [1]

[16]	张远丽, 陈明明, 张师前. 2017 ACOG《遗传性乳腺癌卵巢癌综合征》指南解读(卵巢癌篇)[J]. 中国实用妇科与产科杂志, 2017,33(11):1164-1166. DOI:10.19538/j.fk2017110115. 本文引用 [1]

[17]	Nagy R, Sweet K, Eng C. Highly penetrant hereditary cancer syndromes[J]. Oncogene, 2004, 23(38):6445-6470. DOI:10.1038/sj.onc.1207714. 本文引用 [1]

[18]	高显华, 赵子夜, 刘连杰, 等. 林奇综合征的筛查和诊治研究进展[J]. 结直肠肛门外科, 2023, 29(2):115-121. DOI:10.19668/j.cnki.issn1674-0491.2023.02.003. 本文引用 [1]

[19]	Zhao S, Chen L, Zang Y, et al. Endometrial cancer in Lynch syndrome[J]. Int J Cancer, 2022, 150(1):7-17. DOI:10.1002/ijc.33763. 本文引用 [1]

[20]	Bounous VE, Robba E, Perotto S, et al. Gynecological cancers in Lynch syndrome:a comparison of the histological features with sporadic cases of the general population[J]. J Clin Med, 2022, 11(13):3689. DOI:10.3390/jcm11133689. 本文引用 [1]

[21]	林奇综合征相关妇科肿瘤综合管理中国专家共识制定专家组. 林奇综合征相关妇科恶性肿瘤综合管理中国专家共识(2025年版)[J]. 肿瘤学杂志, 2025, 31(1):2-14.DOI:10.11735/j.issn.1671-170X.2025.01.B001. 本文引用 [2]

[22]	Aaltonen LA, Salovaara R, Kristo P, et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease[J]. N Engl J Med, 1998, 338(21):1481-1487. DOI:10.1056/NEJM199805213382101. 本文引用 [1]

[23]	Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer(Lynch syndrome) and microsatellite instability[J]. J Natl Cancer Inst, 2004, 96(4):261-268. DOI:10.1093/jnci/djh034. 本文引用 [1]

[24]	Bourke B, Broderick A, Bohane T. Peutz-Jeghers syndrome and management recommendations[J]. Clin Gastroenterol Hepatol, 2006, 4(12):1550. DOI:10.1016/j.cgh.2006.09.028. 本文引用 [1]

[25]	Kopacova M, Tacheci I, Rejchrt S, et al. Peutz-Jeghers syndrome:diagnostic and therapeutic approach[J]. World J Gastroenterol, 2009, 15(43):5397-5408. DOI:10.3748/wjg.15.5397. 本文引用 [1]

[26]	van Lier MG, Wagner A, Mathus-Vliegen EM, et al. High cancer risk in Peutz-Jeghers syndrome:a systematic review and surveillance recommendations[J]. Am J Gastroenterol, 2010, 105(6):1258-1265. DOI:10.1038/ajg.2009.725. 本文引用 [1]

[27]	Syngal S, Brand RE, Church JM, et al. ACG clinical guideline:Genetic testing and management of hereditary gastrointestinal cancer syndromes[J]. Am J Gastroenterol, 2015, 110(2):223-263. DOI:10.1038/ajg.2014.435. 本文引用 [1]

[28]	李玉婵, 安彦军. Cowden综合征一例诊断体会[J]. 中华消化内镜杂志, 2016, 33(7):488-489. DOI:10.3760/j.issn0254-1432.2006.04. 本文引用 [1]

[29]	李博, 戴艳, 阮光洪. Cowden综合征1例[J]. 中国皮肤性病学杂志, 2021, 35(1):70-72. DOI:10.13735/j.cjdv.1001-7089.202003127. 本文引用 [1]

[30]	李佳, 何玲玲. 1例由胃肠道息肉确诊Cowden综合征的诊断体会及文献复习[J]. 现代临床医学, 2025, 51(2):100-102. DOI:10.11851/j.issn.1673-1557.2025.02.006. 本文引用 [1]

[31]	Hendricks LAJ, Hoogerbrugge N, Schuurs-Hoeijmakers JHM, et al. A review on age-related cancer risks in PTEN hamartoma tumor syndrome[J]. Clin Genet, 2021, 99(2):219-225. DOI:10.1111/cge.13875. 本文引用 [1]

[32]	NCCN Guidelines Version 3.2025. Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic,and Prostate[EB/OL]. [2025-5-24]. https://www.nccn.org/guidelines/guidelines-detail?category=2&id=1545. https://www.nccn.org/guidelines/guidelines-detail?category=2&id=1545 本文引用 [1]

[33]	张颐, 宋玉丽, 李芳梅, 等. 延胡索酸水合酶缺陷型子宫平滑肌瘤诊治的中国专家共识(2023年版)[J]. 癌症进展, 2023, 21(14):1509-1514+1542. DOI:10.11877/j.issn.1672-1535.2023.21.14.01. 本文引用 [2]

[34]	Lau HD, Chan E, Fan AC, et al. A clinicopathologic and molecular analysis of fumarate hydratase-deficient renal cell carcinoma in 32 patients[J]. Am J Surg Pathol, 2020, 44(1):98-110. DOI:10.1097/PAS.0000000000001372. 本文引用 [1]

[35]	Siegler L, Erber R, Burghaus S, et al. Fumarate hydratase(FH) deficiency in uterine leiomyomas:recognition by histological features versus blind immunoscreening[J]. Virchows Arch, 2018, 472(5):789-796. DOI:10.1007/s00428-018-2292-6. 本文引用 [2]

[36]	Yu Y, Zheng M, Zhu W, et al. Hereditary leiomyomatosis and renal cell cancer(HLRCC):Case series and review of the literature[J]. Urol Oncol, 2021, 39(11):791.e799-791.e716.DOI:10.1016/j.urolonc.2021.07.026. 本文引用 [1]

[37]	Patel VM, Handler MZ, Schwartz RA, et al. Hereditary leiomyomatosis and renal cell cancer syndrome:An update and review[J]. J Am Acad Dermatol, 2017, 77(1):149-158.DOI:10.1016/j.jaad.2017.01.023. 本文引用 [1]

[38]	Kim J, Haley J, Hatton JN, et al. A genome-first approach to characterize DICER1 pathogenic variant prevalence,penetrance and cancer,thyroid,and other phenotypes in 2 population-scale cohorts[J]. Genet Med Open, 2024,2:101846. DOI:10.1016/j.gimo.2024.101846. 本文引用 [1]

[39]

Brenneman M, Field A, Yang J, et al. Temporal order of RNase IIIb and loss-of-function mutations during development determines phenotype in pleuropulmonary blastoma / DICER1 syndrome:a unique variant of the two-hit tumor suppression model[J]. F1000Res, 2015,4:214. DOI:10.12688/f1000research.6746.2. 本文引用 [1]

[40]	吴荧宸, 何冬梅, 谢梅青. DICER1综合征在妇科系统表型的研究进展[J]. 岭南急诊医学杂志, 2020, 25(5):552-554. DOI:10.3969/j.issn.1671-301X.2020.05.043. 本文引用 [1]

[41]	Bauer AJ, Stewart DR, Kamihara J, et al. DICER1 and Associated conditions:identification of at-risk individuals and recommended surveillance strategies-response[J]. Clin Cancer Res, 2019, 25(5):1689-1690. DOI:10.1158/1078-0432.CCR-18-3495. 本文引用 [1]

[42]	Watanabe T, Soeda S, Endo Y, et al. Rare Hereditary gynecological cancer syndromes[J]. Int J Mol Sci, 2022, 23(3):1563. DOI:10.3390/ijms23031563. 本文引用 [1]

[43]	Kolin DL, Dong F, Baltay M, et al. SMARCA4-deficient undifferentiated uterine sarcoma(malignant rhabdoid tumor of the uterus):a clinicopathologic entity distinct from undifferentiated carcinoma[J]. Mod Pathol, 2018, 31(9):1442-1456. DOI:10.1038/s41379-018-0049-z. 本文引用 [2]

[44]	Del Baldo G, Carta R, Alessi I, et al. Rhabdoid tumor predisposition syndrome:from clinical suspicion to general management[J]. Front Oncol, 2021,11:586288. DOI:10.3389/fonc.2021.586288. 本文引用 [1]

[45]	高庆蕾. 卵巢癌与基因检测的规范化[J]. 中国实用妇科与产科杂志, 2021, 37(6):605-609. DOI:10.19538/j.fk2021060102. 本文引用 [1]

[46]	《基于下一代测序技术的BRCA基因检测流程中国专家共识》编写组. 基于下一代测序技术的BRCA基因检测流程中国专家共识[J]. 中华病理学杂志, 2018, 47(6):401-406. DOI:10.3760/cma.j.issn.0529-5807.2018.06.003. 本文引用 [1]

[47]	欧阳振波, 尹倩, 钟碧婷, 等. ASCO关于上皮性卵巢癌胚系和体系肿瘤检测的指南解读[J]. 现代妇产科进展, 2021, 30(2):143-145+149. DOI:10.13283/j.cnki.xdfckjz.2021.02.010. 本文引用 [1]

[48]	Tan MH, Mester JL, Ngeow J, et al. Lifetime cancer risks in individuals with germline PTEN mutations[J]. Clin Cancer Res, 2012, 18(2):400-407. DOI:10.1158/1078-0432.CCR-11-2283. 本文引用 [1]

[49]	姜婷婷, 钱建华. 遗传性子宫内膜癌的研究进展[J]. 实用肿瘤杂志, 2020, 35(4):306-309. DOI:10.13267/j.cnki.syzlzz.2020.04.005. 本文引用 [1]

[50]	Ishida H, Tajima Y, Gonda T, et al. Update on our investigation of malignant tumors associated with Peutz-Jeghers syndrome in Japan[J]. Surg Today, 2016, 46(11):1231-1242. DOI:10.1007/s00595-015-1296-y. 本文引用 [1]

[51]	Meserve EE, Nucci MR. Peutz-Jeghers syndrome:pathobiology, pathologic manifestations,and suggestions for recommending genetic testing in pathology reports[J]. Surg Pathol Clin, 2016, 9(2):243-268. DOI:10.1016/j.path.2016.01.006. 本文引用 [1]

[52]	中国人体健康科技促进会生育力保护与保存专业委员会, 中国医院协会妇产医院分会, 国际妇科内分泌学会中国妇科内分泌学分会, 等. 医源性早发性卵巢功能不全临床治疗与管理指南(2025年版)[J]. 中国实用妇科与产科杂志, 2025, 41(1):76-87. DOI:10.19538/j.fk2025010120. 本文引用 [1]

[53]	Gayther SA, Pharoah PD. The inherited genetics of ovarian and endometrial cancer[J]. Curr Opin Genet Dev, 2010, 20(3):231-238. DOI:10.1016/j.gde.2010.03.001. 本文引用 [2]

[54]	Mersch J, Brown N, Pirzadeh-Miller S, et al. Prevalence of variant reclassification following hereditary cancer genetic testing[J]. JAMA, 2018, 320(12):1266-1274. DOI:10.1001/jama.2018.13152. 本文引用 [1]

[55]	Rosenthal AN, Fraser LSM, Philpott S, et al. Evidence of stage shift in women diagnosed with ovarian cancer during phase ⅱ of the united kingdom familial ovarian cancer screening study[J]. J Clin Oncol, 2017, 35(13):1411-1420. DOI:10.1200/JCO.2016.69.9330. 本文引用 [1]

[56]	中国老年保健协会妇科肿瘤专业委员会, 中国医师协会妇产科医师分会. 卵巢癌早期筛查中国专家共识(2025年版)[J]. 中国实用妇科与产科杂志, 2025, 41(2):204-211. DOI:10.19538/j.fk2025020113. 本文引用 [1]

[57]	中国医师协会妇产科医师分会妇科肿瘤学组. 子宫颈胃型腺癌临床诊治中国专家共识(2023年版)[J]. 中国实用妇科与产科杂志, 2023, 39(6):617-625. DOI:10.19538/j.fk2023060111. 本文引用 [1]

[58]	Friebel TM, Domchek SM, Rebbeck TR. Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers:systematic review and meta-analysis[J]. J Natl Cancer Inst, 2014, 106(6):dju091. DOI:10.1093/jnci/dju091. 本文引用 [1]

[59]	Phillips KA, Kotsopoulos J, Domchek SM, et al. Hormonal contraception and breast cancer risk for carriers of germline mutations in BRCA1 and BRCA2[J]. J Clin Oncol, 2025, 43(4):422-431. DOI:10.1200/JCO.24.00176. 本文引用 [1]

[60]	World Health Organization. Medical eligibility criteria for contraceptive use,Fifth edition[EB/OL].( 2015-2-3). [2025-5-24]. https://www.who.int/publications/i/item/9789241549158. https://www.who.int/publications/i/item/9789241549158 本文引用 [1]

[61]

Collaborative Group on Epidemiological Studies on Endometrial Cancer. Endometrial cancer and oral contraceptives:an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies[J]. Lancet Oncol, 2015, 16(9):1061-1070. DOI:10.1016/S1470-2045(15)00212-0. 本文引用 [1]

[62]	Dumesic DA, Lobo RA. Cancer risk and PCOS[J]. Steroids, 2013, 78(8):782-785. DOI:10.1016/j.steroids.2013.04.004. 本文引用 [1]

[63]	Xiao YL, Wang K, Liu Q, et al. Risk reduction and survival benefit of risk-reducing salpingo-oophorectomy in hereditary breast cancer:meta-analysis and systematic review[J]. Clin Breast Cancer, 2019, 19(1):e48-e65. DOI:10.1016/j.clbc.2018.09.011. 本文引用 [1]

[64]	Reitsma W, de Bock GH, Oosterwijk JC, et al. Support of the “fallopian tube hypothesis” in a prospective series of risk-reducing salpingo-oophorectomy specimens[J]. Eur J Cancer, 2013, 49(1):132-141. DOI:10.1016/j.ejca.2012.07.021. 本文引用 [1]

[65]	Hall E, Finch A, Jacobson M, et al. Effects of bilateral salpingo-oophorectomy on menopausal symptoms and sexual functioning among women with a BRCA1 or BRCA2 mutation[J]. Gynecol Oncol, 2019, 152(1):145-150. DOI:10.1016/j.ygyno.2018.10.040. 本文引用 [1]

[66]	Vermeulen RFM, Beurden MV, Kieffer JM, et al. Hormone replacement therapy after risk-reducing salpingo-oophorectomy minimises endocrine and sexual problems:A prospective study[J]. Eur J Cancer, 2017, 84:159-167. DOI:10.1016/j.ejca.2017.07.018. 本文引用 [1]

[67]	Michelsen TM, Tonstad S, Pripp AH, et al. Coronary heart disease risk profile in women who underwent salpingo-oophorectomy to prevent hereditary breast ovarian cancer[J]. Int J Gynecol Cancer, 2010, 20(2):233-239. DOI:10.1111/igc.0b013e3181ca5ff4. 本文引用 [1]

[68]	Medeiros F, Muto MG, Lee Y, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome[J]. Am J Surg Pathol, 2006, 30(2):230-236. DOI:10.1097/01.pas.0000180854.28831.77. 本文引用 [1]

[69]	Long Roche KC, Abu-Rustum NR, Nourmoussavi M, et al. Risk-reducing salpingectomy:Let us be opportunistic[J]. Cancer, 2017, 123(10):1714-1720. DOI:10.1002/cncr.30528. 本文引用 [1]

[70]	Dietl J, Wischhusen J, Geissinger E. The fimbria/ovarian surface junction[J]. Hum Reprod, 2011, 26(12):3494-3495. DOI:10.1093/humrep/der337. 本文引用 [1]

[71]	Kwon JS, Tinker A, Pansegrau G, et al. Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers[J]. Obstet Gynecol, 2013, 121(1):14-24. DOI:10.1097/aog.0b013e3182783c2f. 本文引用 [1]

[72]	Holman LL, Friedman S, Daniels MS, et al. Acceptability of prophylactic salpingectomy with delayed oophorectomy as risk-reducing surgery among BRCA mutation carriers[J]. Gynecol Oncol, 2014, 133(2):283-286. DOI:10.1016/j.ygyno.2014.02.030. 本文引用 [1]

[73]	Arts-de Jong M, Harmsen MG, Hoogerbrugge N, et al. Risk-reducing salpingectomy with delayed oophorectomy in BRCA1/2 mutation carriers:patients' and professionals' perspectives[J]. Gynecol Oncol, 2015, 136(2):305-310. DOI:10.1016/j.ygyno.2014.12.031. 本文引用 [1]

[74]	Kim H, Choi DH, Park W, et al. The association between non-breast and ovary cancers and BRCA mutation in first- and second-degree relatives of high-risk breast cancer patients:a large-scale study of Koreans[J]. Hered Cancer Clin Pract, 2019,17:1. DOI:10.1186/s13053-018-0103-3. 本文引用 [1]

[75]	Duffy DL, Antill YC, Stewart CJ, et al. Report of Endometrial Cancer in Australian BRCA1 and BRCA2 mutation-positive Families[J]. Twin Res Hum Genet, 2011, 14(2):111-118. DOI:10.1375/twin.14.2.111. 本文引用 [1]

[76]	Watson P, Vasen HFA, Mecklin JP, et al. The risk of extra-colonic,extra-endometrial cancer in the Lynch syndrome[J]. Int J Cancer, 2008, 123(2):444-449. DOI:10.1002/ijc.23508. 本文引用 [1]

[77]	Aarnio M, Sankila R, Pukkala E, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes[J]. Int J Cancer, 1999, 81(2):214-218. 本文引用 [1]

[78]	Bogani G, Tagliabue E, Signorelli M, et al. Assessing the risk of occult cancer and 30-day morbidity in women undergoing risk-reducing surgery:a prospective experience[J]. J Minim Invasive Gynecol, 2017, 24(5):837-842. DOI:10.1016/j.jmig.2017.04.017. 本文引用 [1]

[79]	Schmeler KM, Lynch HT, Chen LM, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome[J]. N Engl J Med, 2006, 354(3):261-269. DOI:10.1056/NEJMoa052627. 本文引用 [1]

[80]	NCCN Guidelines Version 4.2024. Genetic/Familial High-Risk Assessment: Colorectal, Endometrial,and Gastric[EB/OL]. [2025-5-23]. https://www.nccn.org/guidelines/guidelines-detail?category=2&id=1544. https://www.nccn.org/guidelines/guidelines-detail?category=2&id=1544 本文引用 [1]

[81]

Manchanda R, Gaba F, Talaulikar V, et al. Risk-reducing salpingo-oophorectomy and the use of hormone replacement therapy below the age of natural menopause:scientific impact paper No. 66 October 2021:scientific impact paper No. 66[J]. BJOG, 2022, 129(1):e16-e34. DOI:10.1111/1471-0528.16896. 本文引用 [1]

[82]	Lubián López DM. Management of genitourinary syndrome of menopause in breast cancer survivors:An update[J]. World J Clin Oncol, 2022, 13(2):71-100. DOI:10.5306/wjco.v13.i2.71. 本文引用 [1]

[83]	Titus S, Li F, Stobezki R, et al. Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans[J]. Sci Transl Med, 2013, 5(172):172ra121. DOI:10.1126/scitranslmed.3004925. 本文引用 [1]

[84]	Wang ET, Pisarska MD, Bresee C, et al. BRCA1 germline mutations may be associated with reduced ovarian reserve[J]. Fertil Steril, 2014, 102(6):1723-1728. DOI:10.1016/j.fertnstert.2014.08.014. 本文引用 [1]

[85]	Lin WT, Beattie M, Chen LM, et al. Comparison of age at natural menopause in BRCA1/2 mutation carriers with a non-clinic-based sample of women in northern California[J]. Cancer, 2013, 119(9):1652-1659. DOI:10.1002/cncr.27952. 本文引用 [1]

[86]	中国抗癌协会生育力保护专业委员会. 妇科恶性肿瘤生育力保护与保存临床路径(2025年版)[J]. 中国实用妇科与产科杂志, 2025, 41(7):723-729. DOI:10.19538/j.fk2025070112. 本文引用 [1]

[87]	中国抗癌协会家族遗传性肿瘤专业委员会. 中国家族遗传性肿瘤临床诊疗专家共识(2021年版)(2)—家族遗传性卵巢癌[J]. 中国肿瘤临床, 2021, 48(24):1243-1247. DOI:10.12354/j.issn.1000-8179.2021.20211800. 本文引用 [2]

[88]	Hoskovec JM, Bennett RL, Carey ME, et al. Projecting the Supply and Demand for Certified Genetic Counselors:a Workforce Study[J]. J Genet Couns, 2018, 27(1):16-20. DOI:10.1007/s10897-017-0158-8. 本文引用 [1]

[89]	Chan JL, Johnson LNC, Sammel MD, et al. Reproductive decision-making in women with BRCA1/2 mutations[J]. J Genet Couns, 2017, 26(3):594-603. DOI:10.1007/s10897-016-0035-x. 本文引用 [2]

[90]	Daina G, Ramos L, Obradors A, et al. First successful double-factor PGD for Lynch syndrome:monogenic analysis and comprehensive aneuploidy screening[J]. Clin Genet, 2013, 84(1):70-73. DOI:10.1111/cge.12025. 本文引用 [1]